An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03460782|
Expanded Access Status : Available
First Posted : March 9, 2018
Last Update Posted : February 11, 2019
|Condition or disease||Intervention/treatment|
|Glioblastoma Glioma of Brain||Biological: Ipilimumab|
It is not yet known which protocols are a better treatment for glioblastoma or glioma.
The ipilimumab extended-access program for patients who received previous chemotherapy and / or radiation therapy by protocol, before ((for non-operable cases) or after the operation.
Monoclonal antibodies of CTLA-4, such as ipilimumab, may block tumor growth in different ways by targeting certain cells and activating the patient's immune system to fight the disease.
|Study Type :||Expanded Access|
|Expanded Access Type :||Individual Patients|
|Official Title:||An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas|
- Biological: Ipilimumab
Each patient receives Ipilimumab in regimen and dose according to the official manufacturer's instructions (IV 1 mg / kg every 6 weeks for maximum of 4 doses).
Participation of the patient in the program must necessarily be agreed with the current treatment and contain a written agreement with the attending physician.
This program is not covered by health insurance. For patients in the postoperative period to provide a mandatory conclusion of histology and molecular-genetic for the identified mutations and the type of tumor.Other Name: MDX-010
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03460782
|Contact: Daniel M Cherrett||508 786 670 ext email@example.com|
|Contact: Elizabeth Wonemeyer||443 665 firstname.lastname@example.org|
|University "Mother Theresa" Hospital Center; Oncology Department|
|Tirana, Albania, 1000|
|Bosnia and Herzegovina|
|University Clinical Center of the Republic of Srpska|
|Banja Luka, Bosnia and Herzegovina, 78000|
|Complex Oncology Center|
|Plovdiv, Bulgaria, 4004|
|Clinical Hospital Osijek; Dept For Oncology & Radiotherapy|
|Osijek, Croatia, 31000|
|Institut of Oncology Al. Trestioreanu Bucharest; Oncology|
|Bucharest,, Romania, 022338|
|Regional Oncology Hospital|
|Irkutsk, Russian Federation, 664035|
|Rostov Cancer Research Institute|
|Rostov-on-Don, Russian Federation, 344037|
|Primorsky Regional Oncology Center|
|Vladivostok, Russian Federation, 690069|
|Clinical Hospital Center Bezanijska kosa; Clinic for Oncology|
|Belgrade, Serbia, 11 000|
|Inselspital Bern; Medizinische Onkologie|
|Bern, Switzerland, 3010|
|Stadtspital Triemli; Frauenklinik|
|Zürich, Switzerland, 8063|